Skip to content

Ketamine for depression: all studies

Page 123 of 154: studies 1,221 to 1,230 of 1,534, newest first. Back to the ketamine for depression overview

Research

Ketamine in depression and electroconvulsive therapy

Current Opinion in Anaesthesiology October 1, 2021 Irene Rozet 9 citations

Purpose of review The antidepressant effect of subanesthetic doses of ketamine was recognized 20 years ago. This review briefly summarizes the current understanding of the antidepressant mechanisms and the available clinical research on the use of racemic ketamine and enantiomer esketamine for depression. Recent findings The antidepressant effect of subanesthetic doses of ketamine is currently...

NOVEL MANAGEMENT OF DEPRESSION USING KETAMINE IN THE INTENSIVE CARE UNIT

medRxiv Preprint Server September 23, 2021 Nirmaljot Kaur, Siva Naga S. Yarrarapu, Abhishek R. Giri et al. preprint

Background Ketamine, a dissociative anesthetic, induces remission of depression by antagonizing glutaminergic NMDA receptors. Ketamine has been used previously in outpatient setting for treatment-resistant depression, but we showcase its utility in depression management at the Intensive Care Unit (ICU).

DOI: 10.1101/2021.09.23.21262316 (opens in new tab) Full text (opens in new tab) Ketamine depression treatment Intensive care psychiatry Rapid antidepressant effect Novel therapies

Plasma inflammatory cytokines and treatment-resistant depression with comorbid pain: improvement by ketamine

Journal of Neuroinflammation September 15, 2021 Yanling Zhou, Chengyu Wang, Xiaofeng Lan et al. 61 citations

Treatment-resistant depression (TRD) and pain frequently coexist clinically. Ketamine has analgesic and antidepressant effects, but few studies have evaluated individual differences in antidepressant outcomes to repeated ketamine in TRD patients with comorbid pain. Our aims were to determine the difference in ketamine’s antidepressant effects in TRD patients with or without pain and then to...

Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.

Cochrane Database of Systematic Reviews September 12, 2021 Rebecca L. Dean, Claudia C. Hurducas, Keith Hawton et al. 97 citations

BACKGROUND Many studies have recently been conducted to assess the antidepressant efficacy of glutamate modification in mood disorders. This is an update of a review first published in 2015 focusing on the use of glutamate receptor modulators in unipolar depression. OBJECTIVES To assess the effects - and review the acceptability and tolerability - of ketamine and other glutamate receptor...

miR-98-5p plays a critical role in depression and antidepressant effect of ketamine

Translational Psychiatry September 3, 2021 Chao Huang, Yuanyuan Wang, Zifeng Wu et al. 29 citations

Ketamine has been demonstrated to be a rapid-onset and long-lasting antidepressant, but its underlying molecular mechanisms remain unclear. Recent studies have emerged microRNAs as important modulators for depression treatment. In this study, we report that miR-98-5p is downregulated in the prefrontal cortex and hippocampus of mice subjected to chronic social stress, while overexpressing it by...

KETAMINE THERAPY COMBINED WITH REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (rTMS) FOR MAJOR DEPRESSIVE DISORDER AT A SUBURBAN TERTIARY CLINIC

Brain Stimulation September 1, 2021 M. Davila, A. Hess, Ananya Louviere et al.

Background: Repetitive transcranial magnetic stimulation (rTMS) is a neurostimulatory technique approved for the treatment of major https://doi.org/10.1016/j.brs.2021.07.023 depressive disorder (MDD) impacting orbital frontal cortex functioning. We have previously identified significant changes in ratings for several standard metrics for depression, anxiety, pain and ADHD after 6 weeks of...

Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review

Cureus August 21, 2021 Alisha Sapkota, Hajra Khurshid, Israa A Qureshi et al. 44 citations

Intranasal form of esketamine, the S-enantiomer of racemic ketamine, was approved by the US FDA in 2019 for treatment-resistant depression (TRD) in adults. Since intranasal esketamine is a newly approved drug with a novel mechanism of action, much still remains unknown in regard to its use in TRD. The objective of this study is to systematically review the latest existing evidence on intranasal...

Efficacy of Oral Ketamine Combined with Psychotherapy for Treatment Resistant Depression

European Journal of Medical and Health Sciences August 5, 2021 Tatiana Zydb, Michael Hart 4 citations

Background: Treatment resistant depression (TRD) is defined as a major depressive episode that does not improve in response to at least two trials, each of a different class, of antidepressant medication. Pharmacotherapy of TRD with low dose ketamines has been shown as relatively successful in recent studies. Effects of such pharmacotherapy can be augmented by combining ketamine with...

Efficacy of low-dose ketamine infusion in anxious vs nonanxious depression: revisiting the Adjunctive Ketamine Study of Taiwanese Patients with Treatment-Resistant Depression

CNS Spectrums August 1, 2021 Mu-Hong Chen, Wei-Chen Lin, Hui-Ju Wu et al.

AbstractBackgroundThe antidepressant effect of low-dose ketamine infusion on Taiwanese patients with anxious vs nonanxious treatment-resistant depression (ANX-TRD vs NANX-TRD) has remained unknown.MethodsIn total, 71 patients with TRD were randomized to three groups. Each group had participants who received saline infusions mixed with 0 (a normal saline infusion), 0.2, and 0.5 mg/kg of...

Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression: An Open-Label Naturalistic Observational Study

Neuropsychiatric Disease and Treatment August 1, 2021 Alina Wilkowska, A. Włodarczyk, Maria Gałuszko‐węgielnik et al. 33 citations

Purpose Bipolar disorder is a chronic and recurrent condition often associated with treatment resistance and suicidality. There is an unmet need for effective treatment in this group of patients. Ketamine has been demonstrated to have antidepressant and antisuicidal properties in unipolar depression. Most of the available studies concern unipolar depression. Here, we present the efficacy and...